Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 
1661 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarcoma
ChiCTR-PRC-08000244: A randomized, controlled, multi-center study evaluating combined operation modality vs imatinib alone (COMVIA) in patients with recurrent/metastatic c-kit positive gastrointestinal stromal tumor

Completed
4
210
 
imatinib + surgery ;imatinib
Cancer hospital affiliated to Fudan University; Beijing Novartis Pharma Co., Ltd., Beijing Novartis Pharma Co.,Ltd. Cancer hospital affiliated to Fudan University
gastrointestinal stromal tumor(GIST)
 
 
2013-000052-17: Study to investigate the early prediction of toxicity following chemotherapy and differences in drug handling in Ewing's sarcoma patients

Ongoing
4
120
Europe
Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Ifosfamide, Powder for solution for injection, Concentrate for solution for infusion, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Cyclophosphamide, Eposin, Doxorubicin Hydrochloride, Vincristine Sulphate, Ifosfamide
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Ewing sarcoma patients, Bone cancer, Diseases [C] - Cancer [C04]
 
 
2014-001044-38: To study the effect of coca-cola on the exposure to imatinib in patients who underwent major gastrectomy.

Ongoing
4
11
Europe
Glivec
Radboud University Nijmegen Medical Center, Radboud University Nijmegen Medical Center
Patients who are treated or will be treated with imatinib, who previously underwent major gastrectomy., Patients who are treated or will be treated with imatinib, who previously underwent major gastrectomy., Diseases [C] - Cancer [C04]
 
 
2014-001561-27: Neuropathy caused by vincristine in children with leukemia: comparing one-hour infusions with short-term infusions Neuropathie door vincristine bij kinderen met leukemie: één-uurs infusen vergeleken met kortdurende infusies

Ongoing
4
88
Europe
Vincristine sulfate, Vincristine Sulphate, VCR, Solution for infusion, Solution for injection
VU university medical center, The Netherlands Organisation for Health Research and Development (in Dutch: ZonMw)
Pediatric oncology, acute lymphoblastic leukemia, nephroblastoma, medulloblastoma, low-grade glioma, Hodgkin lymphoma, rhabdomyosarcoma Kinderoncologie, acute lymfatische leukemie, nefroblastoom, medulloblastoom, laaggradig glioom, Hodgkin lymfoom en rhabdomyosarcoom, Childhood cancer Kinderkanker, Diseases [C] - Cancer [C04]
 
 
2006-005644-92: ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, PILOTO, EN FASE II, DE LA COMBINACIÓN DE IFOSFAMIDA Y DOXORRUBICINA LIPOSÓMICA SEGUIDO DE RADIOTERAPIA COMO TRATAMIENTO ANTINEOPLÁSICO NEOADYUVANTE EN PACIENTES CON SARCOMA DE PARTES BLANDAS DE EXTREMIDADES DE ALTO GRADO (OPEN CLINICAL TEST, NOT RANDOMIZED, PILOT, IN PHASE II, OF IFOSFAMIDA AND DOXORRUBICINA LIPOSÓMICA COMBINATION FOLLOWED OF X-RAY LIKE NEOADJUVANT TREATMENT ANTINEOPLÁSICO IN PATIENTS WITH SARCOMA OF SOFT PARTS OF EXTREMITIES OF HIGH DEGREE)

Ongoing
4
36
Europe
Doxorrubicina Liposomal (doxorrubicine liposomal), Ifosfamida, Doxorrubicina liposomal. En el protocolo, el tratamiento está definido por el principio activo (In protocol, treatment is defined only by active substance), Doxorrubicina liposomal. Ifosfamida En el protocolo, el tratamiento está definido por el principio activo (In protocol, treatment is defined only by active substance), Doxorrubicina liposomal. En el protocolo, el tratamiento está definido por el principio activo (In protocol, treatment is defined only by active substance), Doxorrubicina liposomal. Ifosfamida En el protocolo, el tratamiento está definido por el principio activo (In protocol, treatment is defined only by active substance)
Antonio Cubillo Gracián (Servicio de Oncología Médica - Hospital MD Anderson)
PACIENTES CON SARCOMA DE PARTES BLANDAS DE EXTREMIDADES DE ALTO GRADO(PATIENTS WITH OF SOFT PARTS SARCOMA OF HIGH DEGREE EXTREMITIES)
 
 
2011-005554-62: A study investigating the pharmcokintetics (how the body processes with a drug) and pharmcodynamics (what effect the drug has on the body) of the chemotherapy drug doxorubicin, when used to treat children, adolescents and young adults with newly diagnosed cancers: osteosarcoma, Ewing\'s family of tumours, and Hodgkin lymphoma.

Ongoing
4
30
Europe
doxorubicin, Doxorubicin, Doxorubicin, Doxorubicin
Australian Sarcoma Group (ASSG), ASSG (Australian Sarcoma Study Group)
Ewing family of tumoursOsteosarcomaHodgkin lymphoma
 
 
2012-000425-45: Effect van ochtend- of avondinname van sunitinib op de medicijnspiegels in het bloed

Ongoing
4
18
Europe
Sunitinib, Midazolam, EU/1/06/347/001-008, PL 29831/0140, Sutent, Dormicum, Sutent, Dormicum
Renal Cell Cancer, GIST, pancreatic neuroendocrine tumor Niercelcarcinoom, GIST, p-NET
 
 
ChiCTR-RNC-14004667: Study of plasma concentration of Imatinib in Chinese patients with gastrointestinal stromal tumor

Completed
4
300
 
Imatinib
The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Novartis China
Gastrointestinal stromal tumor
 
 
2016-005252-21: Increasing the amount of pazopanib in the blood by splitting intake moments Verhogen van de hoeveelheid pazopanib in het bloed door het spreiden van inname momenten

Ongoing
4
10
Europe
Tablet, Votrient
Netherlands Cancer Institute, Netherlands Cancer Institute
Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Patiënten voor wie behandeling met pazopanib standaard zorg is (gevorderd renaal cel carcinoom of gevorderd weke delen sarcoom)., Patients with advanced renal cell carcinoma or advanced soft-tissue sarcoma Patiënten met nierkanker of weke delen kanker, Diseases [C] - Cancer [C04]
 
 
ChiCTR-OPN-15006162: Detection for effective plasma drug concentration in the field for patients with gastrointestinal stromal tumor with intolerance to 400mg Imatinib

Not yet recruiting
4
200
 
Imatinib 300mg/d ;Imtinib 400mg/d
West China Hospital, Sichuan University; Level of the institution：, none
Gastrointestinal stromal tumor
 
 
ChiCTR-OPC-15006846: Study on preoperative plasma drug concentration for patients with giant gastrointestinal stromal tumors

Not yet recruiting
4
50
 
preoperative IM treatment
Department of gastrointestinal surgery, West China Hospital, Sichuan University; None, none
gastrointestinal stromal tumors
 
 
ChiCTR-OPC-16007953: Clinical study of apatinib mesylate tablets in the treatment of refractory soft tissue sarcoma

Not yet recruiting
4
30
 
Medical and nursing education for patients with soft tissue sarcoma
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Henry csco- Cancer Research Fund
Refractory soft tissue sarcoma
 
 
2017-002437-36: Study for an innovative approach for the monitoring of patients with gastrointestinal stromal tumour treated with imatinib Studio per la valutazione di un nuovo approccio per il monitoraggio di pazienti affetti da tumore stromale gastrointestinale e trattati con il farmaco imatinib

Ongoing
4
58
Europe
imatinib, [035372059], Capsule, hard, GLIVEC - 100 MG 120 CAPSULE RIGIDE USO ORALE
CENTRO DI RIFERIMENTO ONCOLOGICO, Risorse dell'Istituto
Patients with gastrointestinal stromal tumour Pazienti affetti da tumore stromale gastrointestinale, Patients with gastrointestinal stromal tumour Pazienti affetti da tumore stromale gastrointestinale, Diseases [C] - Digestive System Diseases [C06]
 
 
ChiCTR-OPC-17010758: Mesylate apatinib combined with chemotherapy in the treatment of clinical study of osteosarcoma recurrence and metastasis

Recruiting
4
40
 
Apatinib or apatinib + chemotherapy
Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, 经费自筹 Self financing
osteosarcoma
 
 
NCT03932071: Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

Recruiting
4
150
RoW
Zoledronic Acid
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lung Metastases, Tumor Necrosis
01/20
01/23
ChiCTR1900022667: A prospective randomized controlled trial for recombinant human thrombopoietin (rhTPO) at different intervening times to prevent and treat thrombocytopenia after chemotherapy with doxoburicin combined with isocyclophosphamide (AI) regimen in osteosarcoma and soft tissue sarcoma

Not yet recruiting
4
96
 
The patients distributed in group A was treated with rhTPO immediately at a dose of 300 U.d-1.kg-1, ih. ;The patients distributed in group B continued to observe and check blood every other day. When platelets were found to be less than 75*109/L, rhTPO was administered subcutaneously at a dose of 300 U.d-1.kg-1 once a day.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Xisike Clinical Oncology Research Foundation
Osteosarcoma and soft tissue sarcoma
 
 
ChiCTR1800017424: Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study

Recruiting
4
80
 
IFO+EPI regimen ;Pan apatinib scheme
General Hospital of Shenyang Military Area Command; General Hospital of Shenyang Military Area Command, Self-raising
metastatic soft tissue sarcoma
 
 
ChiCTR1900022249: A prospective, single-arm, multi-center study for the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia 3 degrees and above in children with rhabdomyosarcoma or Ewing's sarcoma after chemotherapy

Not yet recruiting
4
30
 
Subcutaneous injection of Mecapegfilgrastim according to the patient's body weight 24-36 hours after chemotherapy
Capital Medical University, Beijing Children's Hospital; Capital Medical University, Beijing Children's Hospital, Researcher self-raising
Neutrophil reduction after chemotherapy
 
 
2020-005751-21: Clinical Trial Extension Study with Avapritinib for Patients with Gastrointestinal Stromal Tumors

Not yet recruiting
4
5
Europe
Avapritinib, BLU-285, Tablet
Blueprint Medicines, Blueprint Medicines
Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumours, Diseases [C] - Cancer [C04]
 
 
ChiCTR1800016574: Comparative study of the efficacy of adriamycin and liposome doxorubicin in the treatment of osteosarcoma

Recruiting
4
150
 
Chemotherapy
Beijing Jishuitan Hospital; Beijing Jishuitan Hospital, None
Osteosarcoma
 
 
ChiCTR-IPR-16008568: A clinical trial for zoledronic acid added into new adjuvant chemotherapy on osteosarcoma patients

Recruiting
4
150
 
zoledronate ;placebo
2nd affiliated hospital of ZheJiang University; 2nd Affiliated Hospital, ZheJiang University, raise independently
osteosarcoma
 
 
ChiCTR1800016838: Clinical trial of secondary prevention of recombinant human thrombopoietin in the prevention of thrombocytopenia in advanced osteosarcoma with apatinib and docetaxel

Recruiting
4
60
 
rhTPO
Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, funding
thrombocytopenia in advanced osteosarcoma
 
 
ChiCTR1800016856: A prospective, randomized, controlled clinical trial of thalidomide against small molecule VEGFR oral targeted drug grade III-IV adverse reactions

Recruiting
4
440
 
Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib ;Apatinib + thalidomide 50~150mg/d, po.QN ;Apatinib ;Anlotinib Hydrochloride + thalidomide 50~150mg/d, po.QN ;Anlotinib
Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Self-raised
Patients with advanced gastric cancer, lung cancer, and osteosarcoma taking apatinib or antatinib
 
 
ChiCTR1800015245: Five Versus Three Years of Adjuvant Imatinib in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor: A Phase III, Randomized, Multicenter Study (FAITH study)

Recruiting
4
380
 
Prolonging the adjuvant duration of imatinib mesylate for 2 years ;not prolong the adjuvant duration and follow up
Sun Yat Sen University, Cancer Center; Sun Yat Sen University, Cancer Center, self-financing
Gastrointestinal Stromal Tumor
 
 
NCT04854018: Indo-cyanine Green (ICG) in Paediatric Oncology MIS

Completed
4
20
Europe
Indocyanine green, Verdye, Diagnostic Green
Birmingham Women's and Children's NHS Foundation Trust
Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Pulmonary Metastasis, Rhabdomyosarcoma, Non-Rhabdo. Soft Tissue Sarcoma
09/22
09/22
ChiCTR1800019995: A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma

Not yet recruiting
4
40
 
Apatinib 250mg, po, qd+Gemcitabine, iv, d1, d8+Paclitaxel, iv, d1
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Self-pay
Advanced Hepatosarcomatoid Carcinoma
 
 
NCT04347122: Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Completed
4
16
US
Tranexamic Acid (TXA)
University of Kansas Medical Center
Musculoskeletal Cancer, Sarcoma,Soft Tissue
08/23
08/23
ChiCTR2100044810: A controlled clinical study the combination of first-line immunotherapy and targeted therapy for advanced sarcomatoid renal cell carcinoma

Recruiting
4
40
 
camrelizumab plus Pazopanib Tablets ;Pazopanib Tablets
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Partially self-financing
Advanced sarcomatoid renal cell carcinoma
 
 
ChiCTR2100044367: Monitoring project of Anlotinib Hydrochloride Capsules (Fu Kewei)

Recruiting
4
1200
 
Nil
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, CTTQ Pharmaceutical Group Co., Ltd.
Non-small cell lung cancer, soft tissue sarcoma, thyroid like cancer or other
 
 
NCT01735955 / 2012-003902-28: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Completed
4
57
Europe, Canada, US, RoW
Nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
07/23
07/23
ChiCTR2100049974: An exploratory clinical study of Camrelizumab combined with AD chemotherapy in the first-line treatment of metastatic or inoperable undifferentiated pleomorphic sarcoma (UPS)

Not yet recruiting
4
30
 
Drug intervention
Peking University Cancer Hospital; Peking University Cancer Hospital, NA
undifferentiated pleomorphic sarcoma
 
 
ChiCTR2100052208: An observational clinical study of ripatinib in the treatment of patients with complex genetically mutated gastrointestinal stromal tumors

Not yet recruiting
4
30
 
Ripatinib
The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University, Zai Lab Pharmaceutical Trading (Suzhou) Co., Ltd.
gastrointestinal stromal tumor
 
 
Li2CO3, NCT01669369: Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma

Recruiting
4
400
RoW
Lithium Carbonate, Lithobid, Placebo, PLACEBO TREATMENT
Sun Yat-sen University, Qilu Hospital of Shandong University, Nanfang Hospital of Southern Medical University, Shenzhen Second People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanghai 6th People's Hospital
Osteosarcoma
12/23
12/23
NCT03244020: LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Enrolling by invitation
4
1434
US
Aspirin 325mg, ASA, Enoxaparin 40Mg/0.4mL Prefilled Syringe, Lovenox
Massachusetts General Hospital
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
12/27
07/28
SDCMK, NCT06236022: The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Recruiting
4
276
RoW
Sirolimus
Tongji Hospital, Wuhan Central Hospital, Wuhan Fourth Hospital, Wuhan University
Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
12/28
12/28
ChiCTR2200060233: A prospective, parallel controlled study of DEB-TACE versus arterial infusion chemotherapy in the treatment of metastatic or recurrent soft tissue sarcoma

Not yet recruiting
4
70
 
Drug elution embolism-Transcatheter arterial chemoembolization, DEB-TACE group ;Arterial infusion chemotherapy
The Fifth Medical Center of PLA General Hospital; The Fifth Medical Center of PLA General Hospital, Beijing Medical Award Foundation
Soft tissue sarcoma
 
 
ChiCTR2100052825: Phase II clinical studies of single center, open, single arm of paclitaxel (albumin binding) in combination with camrelizumab second line and above line treatment of metastatic/locally unresectable soft tissue sarcoma

Not yet recruiting
4
40
 
Camrelizumab and chemotherapy
He'nan Tumor Hospital; He'nan Tumor Hospital, Self-funded
Soft tissue sarcoma
 
 
ChiCTR2300075388: Clinical study of trilaciclib for the prevention of severe myelosuppression after chemotherapy in patients with bone and soft tissue sarcoma

Recruiting
4
550
 
Patients with bone and soft tissue sarcoma who had IV-degree bone marrow suppression in previous chemotherapy did not receive Turacilli for preventive treatment. ;Patients with bone and soft tissue sarcoma who have experienced IV-degree bone marrow inhibition in chemotherapy should receive trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) before the next chemotherapy. ;Patients with bone and soft tissue sarcoma will not receive prophylactic treatment until they plan to receive a high-risk chemotherapy regimen. ;Before patients with bone and soft tissue sarcoma are proposed to receive high-FN-risk chemotherapy, trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) for preventive treatment.
Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Self-finance
Bone and soft tissue sarcoma
 
 
ChiCTR1800017181: A prospective, single-arm, multi-center clinical study of adjuvant treatment of Gastrointestinal Stromal Tumors with Imatinib Mesylate (Gnical)

Not yet recruiting
4
150
 
adjuvant Gastrointestinal Stromal Tumors after Imatinib Mesylate
Henan Provincial People's Hospital; Henan Provincial People's Hospital, enterprise
Gastrointestinal Stromal Tumors
 
 
ChiCTR2000033298: A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with Stage IIB classic osteosarcoma of the extremity

Recruiting
4
52
 
Anlotinib combined with Doxorubicin and cisplatin
West China Hospital of Sichuan University; West China Hospital of Sichuan University, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD
Classic osteosarcoma
 
 
ChiCTR1900023489: The Protection Role of Metformin in Female Reproductive System Development and Fertility Preservation for children with malignant tumors with Chemotherapy: A Double-Blind, Randomized, Placebo-Controlled Study

Not yet recruiting
4
138
 
Placebo ;Metformin
Tongji Medical College, Huazhong University of Science and Technology; Tongji Medical College, Huazhong University of Science and Technology, Foundation of research pioneering project of Tongji hospital
Childhood malignancy (leukemia, lymphoma, rhabdomyosarcoma, etc.)
 
 
NCT04033081: Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®

Recruiting
4
100
US
CivaSheet, brachytherapy, Intraoperative Radiation Therapy
CivaTech Oncology, TAB Clinical
Sarcoma
12/24
12/28
NCT00756509 / 2008-000358-11: Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Active, not recruiting
4
34
Europe
Nilotinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
12/24
12/24
NCT03144206: Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study

Recruiting
4
20
US
Hyperbaric oxygen
Duke University
Sarcoma, Hyperbaric Oxygen Therapy
12/26
12/26
ChiCTR2000033695: A prospective, one-arm, clinical study for letrozole in the treatment of uterine sarcoma

Not yet recruiting
4
20
 
letrozole
International Peace Maternal and Child Health Center affiliated to Shanghai Jiaotong University; International Peace Maternal and Child Health Center affiliated to Shanghai Jiaotong University, International Natural Science Foundation
uterine sarcoma
 
 
NCT04825574: Study for Patients Previously Treated in Avapritinib Clinical Trials

Active, not recruiting
4
5
Europe
Avapritinib, BLU-285
Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
08/25
08/25
NATARS, NCT05844813: Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

Enrolling by invitation
4
102
RoW
Doxorubicin+Ifosfamide+Anlotinib(AI+A), Radical Surgery
Peking University International Hospital, Shanghai Zhongshan Hospital, The Affiliated Hospital of Qingdao University, Peking University First Hospital, Shanghai Cancer Hospital, China, First Affiliated Hospital Xi'an Jiaotong University, Beijing Friendship Hospital
Retroperitoneal Sarcoma
11/25
11/27
NCT01742299 / 2012-002540-25: Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Active, not recruiting
4
155
Europe, US, RoW
imatinib mesylate, STI571
Novartis Pharmaceuticals
GIST and CML
04/33
04/33
ACTRN12609000681257: A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylate

Not yet recruiting
3
350
 
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC)
Gastro-intestinal stromal tumour (GIST)
 
 
ACTRN12621001302842: NanaBis™ an Oro-Buccal Administered delta9-Tetrahydrocannabinol (d9-THC) and Cannabidiol (CBD) Medicine For The Management of Chronic Pain From Metastatic Bone Cancer

Not yet recruiting
3
360
 
Medlab Clinical Ltd , Medlab Clinical Ltd
Cancer, Bone Metastases, Pain Management
 
 
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
ACTRN12624000532505: International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1

Not yet recruiting
3
900
 
University of Birmingham, The Australia Organisation for Young People Living with Cancer (Canteen), Australian Department of Health and Aged Care, Medical Research Future Fund (MRFF) , The Kid’s Cancer Project , Australia and New Zealand Sarcoma Association
Ewing Sarcoma
 
 
ACTRN12608000214336: A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bone Sarcomas.

Recruiting
3
650
 
ARIAD Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc.
Metastatic soft tissue or bone sarcomas
 
 
NACLESS, jRCTs031220446: JCOG2102: Randomized phase III trial of Neo-adjuvant and adjuvant chemotherapy vs Adjuvant Chemotherapy alone for LocalizEd Soft tissue Sarcoma

Recruiting
3
224
Japan
doxorubicin hydrochloride - Generic mfg., ifosfamide - Generic mfg.
Oita University Hospital, National Cancer Center Japan
Resectable high grade non-round cell soft tissue sarcoma
 
 
NCT00707109: Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
1200
US
trabectedin, Yondelis
University of Medicine and Dentistry New Jersey, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sarcoma
12/09
 
ChiCTR-TNC-09000585: Efficacy of dose escalation in Chinese patients with advanced GIST after 400mg imatinib resistance

Completed
3
52
 
imatinib dose escalation treatment
Beijing Cancer Hospital; Novartis China, Beijing Cancer Hospital foundation, Novartis China
Gastrointestinal stromal tumor
 
 
2010-024425-20: Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor patients receiving Targeted Therapy

Ongoing
3
60
Europe
supersaturated calcium phosphate rinse, MDD93/42/CEE, Oromucosal solution, Caphosol
Leiden University Medical Centre
oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor
 
 
OS2006, NCT00470223 / 2006-003377-27: Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Active, not recruiting
3
318
Europe
cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery
UNICANCER, Novartis, Chugai Pharmaceutical, National Cancer Institute, France, SFCE, Ligue contre le cancer, France
Sarcoma
12/15
12/26
2009-014907-29: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas

Ongoing
3
250
Europe
Doxorubicin, Docetaxel, Gemcitabine,
University College London
Locally advanced unresectable or metastatic soft tissue sarcoma.
 
 
2010-023484-17: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye tratamiento con medicamentos antitumorales estándar comparado con tratamientos específicos para las diferentes variedades histológicas como primer tratamiento.

Ongoing
3
250
Europe
epirrubicina, ifosfamida, Gemcitabina, Docetaxel, Etoposido, FARMIBLASTINA, Dacarbazina, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine
ITALIAN SARCOMA GROUP, Grupo Español de Investigación en Sarcomas, Italian Sarcoma Group, , Grupo Español de Investigación en Sarcomas, NHS (diagnostic and therapeutic procedures), Eurosarc, funded by project/grant FP7
High risk localized soft tissue sarcomas typical of the adult
 
 
2012-002107-17: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing\'s Sarcoma Family of Tumours

Ongoing
3
300
Europe
Vincristine, Ifosfamide, Doxorubicin, Etoposide, Actinomycin D, Cyclophosphamide, Zoledronic acid, Vincristine Sulphate, Ifosfamide, Doxorubicin hydrochloride, Eposin, Cosmegen Lyovac, Cyclophosphamide, Zometa, Vincristine Sulphate, Ifosfamide, Doxorubicin hydrochloride, Eposin, Cosmegen Lyovac, Cyclophosphamide, Zometa
University of Birmingham, CTAAC, FP7
Ewing\'s Sarcoma Family of Tumours
 
 
2014-005255-87: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study. Evaluation de l’efficacité d’un traitement adjuvant par Imatinib chez les patients porteurs d’une tumeur stromale gastro-intestinale de risque intermédiaire présentant un Genomic Index de mauvais pronostic. Etude multicentrique, prospective, randomisée.

Not yet recruiting
3
80
Europe
Glivec, Capsule, Glivec
Assistance Publique Hôpitaux de MARSEILLE, PHRC Cancer 2013
Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index Patient présentant une tumeur stromale gastrointestinale de risuqe intermédaire avec un index génomique élevé, Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index Patient présentant une tumeur stromale gastrointestinale de risuqe intermédaire avec un index génomique élevé, Diseases [C] - Cancer [C04]
 
 
NCT01933932 / 2013-001676-38: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Checkmark SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Aug 2016 - Aug 2016: SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Checkmark Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Jan 2016 - Jan 2016: Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Checkmark Pivotal trial initiation in 2nd-line KRASm NSCLC
More
Active, not recruiting
3
510
Europe, Canada, US, RoW
Selumetinib, AZD6244; ARRY-142886, Docetaxel, Placebo, Pegylated G-CSF, Pegfilgrastim 6 mg
AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
06/16
12/24
acns0333, NCT00653068: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Completed
3
70
Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor
09/16
03/24
NCT00085202: Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed
3
416
Canada, US, RoW
filgrastim, Neupogen(R), G-CSF, cisplatin, Platinol-AQ(R), cyclophosphamide, Cytoxan(R), vincristine, Oncovin(R), autologous hematopoietic stem cell transplantation, autologous HSCT, radiation therapy, RT, Craniospinal radiotherapy
St. Jude Children's Research Hospital
Brain and Central Nervous System Tumors
12/16
12/23
AREN0534, NCT00945009: Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

Active, not recruiting
3
249
Canada, US, RoW
Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor
12/16
 
2016-003214-27: Clinical trial to evaluate blood loss by administering transexamic acid via topical, intravenous, or both in surgically operated patients with osteous or soft tissue sarcomas. Ensayo clínico para evaluar la pérdida de sangre administrando ácido transexámico via tópica, intravenosa u ambas en pacientes intervenidos quirúrgicamente de sarcomas oseos o de partes blandas

Ongoing
3
150
Europe
Amchafibrin, 53939, Concentrate and solvent for solution for injection, Concentrate for dip solution, Amchafibrin
Irene Barrientos Ruiz, Fundacion SECOT
Oncological orthopedic surgery (bone and soft tissue sarcomas in the appendicular skeleton, pelvis and scapular girdle). cirugía ortopédica oncológica (sarcomas óseos y de partes blandas en esqueleto apendicular, pelvis y cintura escapular)., Bone or soft tissue cancer Bone or soft tissue cancer, Diseases [C] - Cancer [C04]
 
 
ACTRN12616001524482: EWING 2008 Clinical trial for the treatment of Localized and Disseminated Ewing sarcoma

Active, not recruiting
3
1383
 
University Clinic in Essen, Rainbows for Kate
Ewing Sarcoma of bone or soft tissue.
 
 
ANNOUNCE, NCT02451943 / 2015-000134-30: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Active, not recruiting
3
509
Europe, Canada, Japan, US, RoW
Olaratumab, LY3012207, Doxorubicin, Placebo
Eli Lilly and Company
Soft Tissue Sarcoma
12/18
07/24
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
2018-000186-36: Phase III trial investigating the potential benefit of intensified peri-operative Chemotherapy in patients with in high-risk CINSARC patients with resectable soft-tissue SARComas

Not yet recruiting
3
334
Europe
Solution for injection, Solution for infusion, DOXORUBICINE, IFOSFAMIDE
Institut Bergonié, Programme Hospitalier de Recherche Clinique en Cancérologie 2016 - DGOS
Resectable, non-metastatic soft-tissue sarcoma (STS), Resectable, non-metastatic soft-tissue sarcoma (STS), Diseases [C] - Cancer [C04]
 
 
NCT00954174: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Active, not recruiting
3
637
US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
GOG Foundation, National Cancer Institute (NCI)
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma
03/19
 
AAML1031, NCT01371981: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting
3
1645
Canada, US, RoW
Asparaginase, ASP-1, Asparaginase II, Asparaginase-E.Coli, Colaspase, Elspar, Kidrolase, L-Asnase, L-ASP, L-Asparaginase, L-Asparagine Amidohydrolase, Laspar, Lcf-ASP, Leucogen, Leunase, MK-965, Paronal, Re-82-TAD-15, Serasa, Spectrila, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, CL 232315, DHAD, DHAQ, Dihydroxyanthracenedione Dihydrochloride, Mitoxantrone Dihydrochloride, Mitoxantroni Hydrochloridum, Mitozantrone Hydrochloride, Mitroxone, Neotalem, Novantrone, Onkotrone, Pralifan, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
03/19
09/27
A091105, NCT02066181: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Checkmark From A091105 clinical trial for rare sarcomas
Mar 2018 - Mar 2018: From A091105 clinical trial for rare sarcomas
Completed
3
87
Canada, US
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Desmoid Fibromatosis
07/19
12/22
2019-003014-13: Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. Intérêt de la chimiothérapie péri-opératoire chez les patients porteurs de sarcomes des tissus mous localisés de grade 1 ou 2, définis à HAUT RISQUE par la signature CINSARC.

Not yet recruiting
3
600
Europe
DOXORUBICIN, IFOSFAMIDE, DACARBAZINE, Solution for infusion, Powder for solution for injection, Powder for solution for infusion
INSTITUT CLAUDIUS REGAUD, Direction Générale de l’Offre de Soins (DGOS)
Soft Tissue Sarcoma Sarcome des tissus mous, Soft Tissue Sarcoma Sarcome des tissus mous, Diseases [C] - Cancer [C04]
 
 
2019-003119-77: Fluorescence with ICG in GIST resections: a pilot study Fluorescentie met ICG in GIST-resecties

Not yet recruiting
3
10
Europe
Powder for solution for infusion, VERDYE 25 mg / VERDYE 50 mg
Leiden University Medical Center, LUMC
GIST Gastrointestinal stromal cell tumour GISTGastrointestinale stroma tumoren, GIST GIST, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
 
 
AEWS1031, NCT01231906: Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Active, not recruiting
3
642
Canada, US, RoW
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dexrazoxane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR-529, ICRF-187, Razoxane (+)-form, Soluble ICRF (L-isomer), Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral), Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
03/20
 
2019-003543-30: A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma

Ongoing
3
250
Europe
Doxorubicin, Epirubicin, Dacarbazin, Ifosfamide, [Doxorubicin], [Epirubicin], [Dacarbazin], [Ifosfamide], Solution for infusion, Solution for injection/infusion, Powder for solution for injection/infusion
European Organisation for Research and Treatment of Cancer, EORTC AISBL/IVZW, European Organisation for the Research and Treatment of Cancer, Anticancer fund
Primary high risk leiomyosarcoma or Liposarcoma of retroperitoneal space or infra-peritoneal spaces of pelvis, Retroperitoneal sarcoma: a sarcoma developed in the back of the belly, next to the kidneys, in a relatively “hidden” location known as the retroperitoneum., Diseases [C] - Cancer [C04]
 
 
2020-002821-28: Study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype Etude d'efficacité du nivolumab + ipilimumab versus pazopanib seul chez des patients atteints d’un sous-type rare de sarcome avancé non résécable ou métastatique

Not yet recruiting
3
96
Europe
Nivolumab, Ipilimumab, Pazopanib, Solution for injection, Film-coated tablet, Opdivo, Yervoy, Votrient
Centre Léon Bérard, BMS
Metastatic or unresectable advanced rare sarcomas Sarcomes rares avancés non résécables ou métastatiques, Metastatic advanced rare sarcomas Sarcomes rares avancés métastatiques, Diseases [C] - Cancer [C04]
 
 
2018-000542-20: Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program

Not yet recruiting
3
214
Europe
Cyclophosphamide, Doxorubicin, Tablet, Solution for infusion, Endoxan
UNICANCER
Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old., Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old., Diseases [C] - Cancer [C04]
 
 
AEWS1221, NCT02306161: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting
3
312
Canada, US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Therapeutic Surgical Procedure, Vincristine, LCR, Leurocristine, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
03/21
09/24
INTRIGUE, NCT03673501 / 2018-001803-35: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting
3
453
Europe, Canada, US, RoW
Ripretinib, DCC-2618, Sunitinib, Sutent
Deciphera Pharmaceuticals LLC
Gastrointestinal Stromal Tumors
09/21
12/24
NCT02847429 / 2015-000287-34: Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

Active, not recruiting
3
120
Europe, US
Crenolanib, Crenolanib Besylate, Placebo
Arog Pharmaceuticals, Inc., Centre Leon Berard, Fox Chase Cancer Center
GIST With D842V Mutated PDGFRA Gene
08/21
08/21
2020-005858-21: tTF-NGR Randomized Study - STS tTF-NGR randomisierte Studie - STS

Not yet recruiting
3
126
Europe
tTF-NGR, Yondelis, ET-743, Solution for infusion in pre-filled syringe, Powder for concentrate for solution for infusion, Yondelis
Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel, ANTUREC Pharmaceuticals GmbH
Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity: grade >/= 1+)., Patients with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs., Diseases [C] - Cancer [C04]
 
 
SAVE, NCT03422198: Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Recruiting
3
188
US
Vaginal Cuff Brachytherapy, best practice, standard of care, standard therapy, Short course vaginal cuff brachytherapy, BRACHYTHERAPY, internal radiation, Internal Radiation Brachytherapy, Internal Radiation Therapy, Radiation Brachytherapy
University of Utah
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma, Uterine Corpus Sarcoma
11/26
10/29
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated
3
32
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar
Gradalis, Inc.
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
01/22
01/22
NCT02565498: Preoperative vs Postoperative IMRT for Extremity/Truncal STS

Active, not recruiting
3
210
Europe, Canada, US
Preoperative intensity modulated radiation therapy, Postoperative intensity modulated radiation therapy
Mount Sinai Hospital, Canada, Princess Margaret Hospital, Canada
Adult Soft Tissue Sarcoma
10/24
05/29
DeFi, NCT03785964 / 2018-001991-39: Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Checkmark Data from DeFi trial for Desmoid Tumors
May 2022 - May 2022: Data from DeFi trial for Desmoid Tumors
Active, not recruiting
3
142
Europe, Canada, US
Nirogacestat oral tablet, PF-03084014, Placebo Oral Tablet
SpringWorks Therapeutics, Inc.
Desmoid Tumor, Aggressive Fibromatosis
04/22
12/24
2021-000125-27: TOLERANCE: a clinical trial on more tolerable treatments for elderly patients with advanced soft tissue sarcoma TOLERANCE: uno studio clinico su trattamenti più tollerabili per pazienti anziani con sarcoma dei tessuti molli avanzato

Ongoing
3
185
Europe, RoW
Doxorubicin, Cyclophosphamide, Prednisolone, [Doxorubicin], [Cyclophosphamide], [Prednisolone], Solution for injection/infusion, Coated tablet, Tablet
EORTC AISBL/IVZW, European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Fonds Cancer (FOCA), Rising Tide Foundation
Advanced/metastatic soft tissue sarcoma Sarcoma avanzato/metastatico dei tessuti molli, Sarcoma Sarcoma, Diseases [C] - Cancer [C04]
 
 
NCT04359550: Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

Not yet recruiting
3
362
NA
Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001), placebo
Lee's Pharmaceutical Limited
High-grade Osteosarcoma
06/22
06/23
2019-004153-93: INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA

Not yet recruiting
3
1018
Europe
Protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered, The protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered
German Paediatric Oncology Group, German Cancer Aid
Ewing Sarcoma, Ewing Sarcoma, Diseases [C] - Cancer [C04]
 
 
METROPHOLYS, NCT04656262 / 2018-001075-20: Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Recruiting
3
132
Europe
Cyclophosphamide, Endoxan, Doxorubicin
Istituto Oncologico Veneto IRCCS, Ministry of Health, Italy
Soft Tissue Sarcoma Adult
07/22
01/23
NCT05561036: A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor

Recruiting
3
72
RoW
Liposome doxorubicin, liposome adriamycin, Saline Solution
Sun Yat-sen University
Desmoid Tumor
12/22
03/23
ECOG-ACRIN EA8143, NCT03055013: Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Checkmark Results for metastatic RCC from PROSPER-RCC trial for ESMO 2022
Nov 2022 - Nov 2022: Results for metastatic RCC from PROSPER-RCC trial for ESMO 2022
Active, not recruiting
3
819
Canada, US, RoW
Nephrectomy, Nivolumab, BMS-936558, MDX1106, Patient Observation, Active Surveillance
National Cancer Institute (NCI), Canadian Cancer Trials Group
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
05/23
06/31
ACTRN12621001756819: Three versus five years of adjuvant Imatinib as treatment for patients with operable gastrointestinal stromal tumour (GIST) with a high risk for recurrence: SSGXXII: A Randomised phase III study

Active, not recruiting
3
25
 
Australasian Gastro-Intestinal Trials Group (AGITG), Medical Research Future Fund - International Clinical Trials Collaboration Grant
Gastrointestinal stromal tumour (GIST)
 
 
ARST1431, NCT02567435: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Active, not recruiting
3
325
Canada, US, RoW
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
06/23
10/24
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
MANTRA, NCT04979442: Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Terminated
3
175
Europe, Canada, US, RoW
RAIN-32, Milademetan, Trabectedin, Yondelis
Rain Oncology Inc
Dedifferentiated Liposarcoma
10/23
10/23
2021-001394-23: Clinical study comparing Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma

Not yet recruiting
3
160
Europe
Milademetan, Trabectedin, DS-3032b, Capsule, Powder for concentrate for solution for infusion
Rain Therapeutics, Inc., Rain Oncology Inc., Rain Therapeuthic Inc, RAIN Therapeutics Inc.
Dedifferentiated liposarcoma, Liposarcoma, Diseases [C] - Cancer [C04]
 
 
APROMISS, NCT03016819 / 2017-001655-31: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma

Active, not recruiting
3
325
Europe, US, RoW
AL3818, Catequentenib, Anlotinib, Dacarbazine, DTIC, AL3818 or placebo
Advenchen Laboratories, LLC
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
12/24
06/25
 

Download Options